[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinal-detachment-rhegmatogenous\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinal-detachment-rhegmatogenous":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,73,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100622673","study-of-imaging-and-molecular-biomarkers-in-uncomplicated-rhegmatogenous-retinal-detachment-100622673",false,"NCT07386678","Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment","Cohort-NHS","Inclusion Criteria:\n\n* Adults ≥18 years\n* Uncomplicated primary rhegmatogenous retinal detachment\n* PVD present\n* No PVR-A\u002FB\u002FC\n* Phakic or pseudophakic.\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years\n* Patients lacking capacity\n* Previous vitrectomy\n* Previous cryopexy\n* Aphakia\n* No fundal view\n* Diabetic retinopathy of any severity\n* Retinal detachment secondary to infective causes e.g. acute retinal necrosis, toxoplasmosis scars\n* Retinal detachment secondary to congenital defects e.g. optic disc pit\u002Fcoloboma\n* Exudative retinal detachment\n* Tractional retinal detachment\n* Ongoing involvement in another ocular trial.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","3 Months","OBSERVATIONAL","Disease or general study area: Uncomplicated rhegmatogenous retinal detachment (RRD) and risk of proliferative vittroretinopathy (PVR)\n\nPurpose and nature of the study:\n\n1. Characterise the cytokine profile of vitreous fluid in uncomplicated RRD.\n2. Develop a risk model to predict development of PVR after retinal detachment surgery using imaging and molecular biomarkers.\n3. To develop deep learning\u002Fartificial intelligence (AI) models for PVR detection in retinal detachment.\n\nInclusion criteria:\n\n50 adult ( ≥18 years) patients with uncomplicated rhegmatogenous retinal detachments without PVR.\n\nWhat participating will involve:\n\nPre- and post-operative assessments and intervention will follow standard of care for patients with rhegmatogenous retinal detachments.\n\nAdditional intervention will include non-invasive imaging of anterior chamber flare, vitreous, wide-field retina, macula optical coherence tomography (OCT) and macula OCT-angiography (OCT-A) as well as, seeking participant's consent on collecting their vitreous fluid at time of their surgery for cytokine analysis.",[25,26,27],"Retinal Detachment Rhegmatogenous","Proliferative Vitreoretinopathy","Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment",[29,30],"Cytokines","Imaging","NOT_YET_RECRUITING","2026-05-05",{"date":34,"type":35},"2026-05-06","ACTUAL",{"date":37,"type":20},"2026-04-27",{"date":39,"type":20},"2027-01-27",{"name":41,"class":42},"University College, London","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100619587","1ry-versus-2ry-ilm-peeling-in-rd-100619587","NCT07346560","1ry Versus 2ry ILM Peeling in RD","Primary Versus Secondary Internal Limiting Membrane Peeling in Uncomplicated Retinal Detachment","Inclusion Criteria:\n\n* Patients with uncomplicated rhegmatogenous retinal detcahment.\n\nExclusion Criteria:\n\n* PVR\n* Recurrent RD\n* Tractional RD\n* Macular hole RD\n* Scleral buckling is indicated\n* Macular scarring\n* Previous PPV",{"count":52,"type":20},100,"INTERVENTIONAL",[55],"NA","Patients with uncomplicated rhegmatogenous retinal detachment will be recruited. All eyes will underwent 23G PPV with silicon oil tamponade. The eyes will be classified into two groups according to the timing of ILM peeling. Group A, ILM peelin will be performed during the first intervention, while in group B, it will be done at the time of silicon oil extraction.",[25,58],"ILM Peeling",[60,61,62],"Retinal detachment","ILM peeling","Proliferative vitroretinopathy","RECRUITING","2026-01-15",{"date":66,"type":35},"2026-01-16",{"date":68,"type":35},"2025-12-15",{"date":70,"type":20},"2027-03",{"name":72,"class":42},"Sohag University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":53,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100595593","air-tamponade-versus-fluorinated-gas-tamponade-for-rhegmatogenous-retinal-detachment-100595593","NCT07034469","Air Tamponade Versus Fluorinated Gas Tamponade for Rhegmatogenous Retinal Detachment","Gas Tamponade Versus Air During Vitrectomy for Rhegmatogenous rEtinal dEtachmeNt; a Randomised Controlled Trial","GREEN","Inclusion Criteria:\n\n* Primary uncomplicated RRD undergoing vitrectomy.\n* Phakic and pseudophakic eyes\n* Retinal breaks superiorly between 3 and 9 o'clock, and that are separated by less than 4 clock hours.\n\nExclusion Criteria:\n\n* Absence of PVD\n* Age 40 years or younger\n* PVR grade C or above\n* Aphakia or anterior chamber lens\n* Retinal breaks greater than 1 clock hour in size\n* Retinal breaks that exist below 3 and 9 o'clock on both the nasal and temporal sides.\n* Retinal breaks at or posterior to the vessel arcades\n* Current or previous -6D myopia or greater (or axial length \\>26millimetres (mm))\n* Chronic RRD judged by the presence of subretinal bands and other signs of -chronicity or by history of visual loss for \\>28 days.\n* Significant inflammation, choroidal detachments, hypotony (\\\u003C6 millimetres of mercury (mmHg) preop)\n* Previous open-globe injury, or endophthalmitis\n* Current or previous posterior uveitis or choroiditis\n* Any intraocular surgical procedure within 4 weeks other than laser\u002Fcryotherapy\n* Any other condition that, in the opinion of the investigator, would prevent the participant from granting informed consent or complying with the protocol.","40 Years",{"count":83,"type":20},150,[55],"TITLE: RCT of air tamponade versus fluorinated gas tamponade for rhegmatogenous retinal detachment DESIGN: Non-inferiority RCT of 150 patients from 10 UK centres AIMS: To assess whether air tamponade is non inferior to gas tamponade for the repair of RRD treated with vitrectomy.\n\nPRIMARY OUTCOME MEASURE: Primary anatomical success with single operation at 24 weeks.",[25],[88,89,90],"retinal detachment","gas tamponade","air","2025-12-18",{"date":93,"type":35},"2025-12-24",{"date":95,"type":20},"2026-03-20",{"date":97,"type":20},"2029-03-20",{"name":99,"class":100},"Liverpool University Hospitals NHS Foundation Trust","OTHER_GOV",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":53,"phases":111,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100579009","phase-2-intravitreal-topotecan-for-prevention-or-treatment-of-proliferative-vitreoretinopathy-in-retinal-detachment-100579009","NCT06818721","Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment","Intravitreal Topotecan for the Prevention or Treatment of Proliferative Vitreoretinopathy in Patients with Rhegmatogenous Retinal Detachment: a Prospective Matched Cohort Study","TOPO-PT","Inclusion Criteria:\n\n1. Patients aged 18 years and older\n2. Patients who undergo pneumatic retinopexy, pars plana vitrectomy and\u002For scleral buckling for rhegmatogenous retinal detachment\n3. Patients who are voluntarily able and willing to participate\n\nPatients undergoing combined phacoemulsification and pars plana vitrectomy and\u002For scleral buckling will also be included. Any surgical technique will be considered, including relaxing retinotomy or retinectomy during pars plana vitrectomy.\n\nExclusion Criteria:\n\n1. Patients with a history of exudative retinal detachment\n2. Patients with severe non-proliferative or proliferative diabetic retinopathy\n3. Patients with other planned ocular surgery following pars plana vitrectomy\n4. Female patients of childbearing age (i.e. less than 50 years old) who intend to become pregnant over the course of the study\n5. Patients with pre-existing bone marrow suppression or cytopenias\n6. Patients with pre-existing interstitial lung disease",{"count":110,"type":20},394,[112],"PHASE2","Intravitreal topotecan exhibits strong anti-inflammatory, anti-proliferative, and anti-fibrotic properties, making it a promising option for preventing and treating proliferative vitreoretinopathy in rhegmatogenous retinal detachment. Preclinical studies have demonstrated its efficacy in proliferative vitreoretinopathy models, where no adverse events have been reported for doses of 5 µg to 30 µg. This prospective, matched cohort study aims to assess the therapeutic efficacy and safety of intravitreal topotecan for preventing and treating proliferative vitreoretinopathy in rhegmatogenous retinal detachment patients.",[25,26],[116,117,118],"topotecan","proliferative vitreoretinopathy","rhegmatogenous retinal detachment","2025-03-03",{"date":121,"type":35},"2025-03-06",{"date":123,"type":20},"2025-03",{"date":125,"type":20},"2027-04",{"name":127,"class":42},"Unity Health Toronto",2]